We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UPLD:NASDAQUpland Software, Inc. Analysis

Data as of 2026-05-07 - not real-time

$0.97

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Upland Software trades at $0.97, far below its DCF‑derived fair value of $8.36, implying an upside of roughly 285% and positioning the stock as deeply undervalued. The company generates solid operating cash flow ($25.8 M) and free cash flow ($33.7 M) despite a recent revenue decline of 27.5%, and its gross margin remains robust at 74.8%. However, profitability is weak (negative net margin –17.9%) and leverage is extreme, with a debt‑to‑equity ratio of 291%, raising concerns about balance‑sheet resilience. Technical indicators show the price above the 20‑day and 50‑day SMAs, a bullish MACD crossover, but an overbought RSI of 71.7, suggesting short‑term pressure may emerge. Recent news adds mixed signals: an earnings miss and a Nasdaq bid‑price deficiency notice increase near‑term risk, while analysts maintain a Buy rating with a $3 target and note free‑cash‑flow outperformance, supporting a longer‑run upside narrative.
Given the extreme volatility (125% 30‑day) and a beta near 2, the stock is highly sensitive to market swings, and the current market sentiment is in the “Extreme Greed” zone. The combination of a distressed balance sheet, high beta, and potential delisting risk elevates the overall risk profile, but the massive valuation gap and positive cash generation provide a compelling case for investors with a higher risk tolerance to consider accumulating the shares for the medium to long term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Recent earnings miss and overbought RSI signal potential pullback
  • Nasdaq bid‑price deficiency notice raises near‑term delisting risk
  • Current price near resistance at $1.06 with limited upside in the next weeks

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong free cash flow generation despite revenue decline
  • Analyst consensus remains bullish with a $3 price target
  • Significant valuation upside (>200%) relative to DCF fair value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value of $8.36 suggests massive long‑run upside
  • AI‑powered SaaS platform positions the company for secular growth
  • Resolution of bid‑price deficiency could unlock further upside

Key Metrics & Analysis

Financial Health

Revenue Growth-27.50%
Profit Margin-17.94%
P/E Ratio1.2
ROE-41.91%
ROA2.20%
Debt/Equity291.41
P/B Ratio-0.6
Op. Cash Flow$25.8M
Free Cash Flow$33.7M
Industry P/E37.2

Technical Analysis

TrendNeutral
RSI71.7
Support$0.52
Resistance$1.06
MA 20$0.68
MA 50$0.67
MA 200$1.60
MACDBullish
VolumeIncreasing
Fear & Greed Index90.93

Valuation

Fair Value$8.36
Target Price$3.75
Upside/Downside285.88%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.90
Volatility125.16%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.